Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
Taoka R, Matsuoka Y, Yamasaki M, Kani N, Honda T, Harada S, Tohi Y, Kato T, Okazoe H, Tsunemori H, Ueda N, Sugimoto M. Taoka R, et al. Among authors: tohi y. Photodiagnosis Photodyn Ther. 2022 Jun;38:102838. doi: 10.1016/j.pdpdt.2022.102838. Epub 2022 Apr 4. Photodiagnosis Photodyn Ther. 2022. PMID: 35381368 Free article.
The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study.
Tohi Y, Kato T, Matsumoto R, Shinohara N, Shiga K, Yokomizo A, Nakamura M, Kume H, Mitsuzuka K, Sasaki H, Egawa S, Matsumura M, Hashine K, Inokuchi J, Eto M, Baba H, Ichikawa T, Kinoshita H, Matsuda T, Kakehi Y, Sugimoto M. Tohi Y, et al. Int J Clin Oncol. 2020 Dec;25(12):2107-2114. doi: 10.1007/s10147-020-01761-3. Epub 2020 Aug 8. Int J Clin Oncol. 2020. PMID: 32770439
Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN study.
Tohi Y, Kato T, Yokomizo A, Mitsuzuka K, Tomida R, Inokuchi J, Matsumoto R, Saito T, Sasaki H, Inoue K, Kinoshita H, Fukuhara H, Maruyama S, Sakamoto S, Tanikawa T, Egawa S, Ichikura H, Abe T, Nakamura M, Kakehi Y, Sugimoto M. Tohi Y, et al. Urol Oncol. 2022 Feb;40(2):56.e9-56.e15. doi: 10.1016/j.urolonc.2021.05.003. Epub 2021 Jun 8. Urol Oncol. 2022. PMID: 34112576
63 results